search
Back to results

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Primary Purpose

Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
RO7300490
Atezolizumab
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Life expectancy of >= 12 weeks.
  • Histologically confirmed diagnosis of locally advanced and/or metastatic solid tumors that are not amenable to standard therapy.
  • Radiologically measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Agreement to provide protocol-specific biopsy material.
  • Adverse Events (AEs) from prior anti-cancer therapy resolved to Grade =<1.
  • Adequate performance status and cardiovascular, hematological, liver, renal and coagulation function.
  • For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating eggs.
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating sperm.

Exclusion Criteria:

  • Known central nervous system (CNS) primary tumors or metastases, including leptomeningeal metastases, unless protocol-specific conditions are met.
  • Active second invasive malignancy within two years prior to screening.
  • Significant cardiovascular/cerebrovascular disease within 6 months prior to study treatment start.
  • Any other diseases, metabolic dysfunction, physical examination finding or clinical laboratory finding that gives reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug.
  • Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
  • Active or history of autoimmune disease.
  • Known hypersensitivity to any of the components of RO7300490 formulation or to components of atezolizumab formulation.
  • Pregnancy, lactation or breastfeeding.
  • Dementia or altered mental status that would prohibit informed consent.
  • Major surgery or significant traumatic injury within 28 days prior to the first study drug administration (excluding biopsies) or anticipation of the need for major surgery during study treatment.
  • Treatment with radiotherapy, chemotherapy, hormonal therapy, targeted therapy, immunotherapy or investigational drug concurrent or within 28 days or 5 half-lives of the drug (whichever is shorter) before the first study drug administration.

Sites / Locations

  • Rigshospitalet; Fase 1 Enhed - OnkologiRecruiting
  • Gustave Roussy
  • Seoul National University HospitalRecruiting
  • Asan Medical CenterRecruiting
  • Clinica Universitaria de Navarra; Servicio de OncologiaRecruiting
  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona
  • Clinica Universidad de Navarra Madrid; Servicio de Oncología
  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz
  • Western General Hospital; Edinburgh Cancer CenterRecruiting
  • Guys and St Thomas Hospital; OHCT Clinical TrialsRecruiting
  • Christie Hospital NHS Trust; Experimental Cancer Medicine TeamRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Part 1: Dose Escalation (RO7300490 Monotherapy)

Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)

Part 3: Dose Expansion (Disease-specific Expansion(s))

Arm Description

Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.

Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.

Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.

Outcomes

Primary Outcome Measures

Percentage of Participants with Adverse Events (AEs) (Parts 1 and 2)
Percentage of Participants with Dose-Limiting Toxicities (DLTs) (Parts 1 and 2)
Objective Response Rate (ORR) (Part 3)

Secondary Outcome Measures

Area Under The Curve (AUC) of RO7300490 (Parts 1, 2 and 3)
Minimum Concentration (Cmin) of RO7300490 (Parts 1, 2 and 3)
Maximum Concentration (Cmax) of RO7300490 (Parts 1, 2 and 3)
Clearance (CL) of RO7300490 (Parts 1, 2 and 3)
Volume of Distribution at Steady State (Vss) of RO7300490 (Parts 1, 2 and 3)
Percentage of Participants with Anti-RO7300490 Antibodies (Parts 1, 2 and 3)
Objective Response Rate (ORR) (Parts 1 and 2)
Disease Control Rate (DCR) (Parts 1, 2 and 3)
Duration of Response (DOR) (Parts 1, 2 and 3)
Progression-Free Survival (PFS) On-Treatment (Parts 1, 2 and 3)
Percentage of Participants With Adverse Events (AEs) (Part 3)

Full Information

First Posted
April 22, 2021
Last Updated
October 13, 2023
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT04857138
Brief Title
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Official Title
An Open-Label, Multicenter, Dose-Escalation and Expansion, Phase I Study to Evaluate Safety, Pharmacokinetics, And Anti-Tumor Activity of RO7300490, A Fibroblast Activation Protein-α (FAP) Targeted CD40 Agonist, as Single Agent or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 18, 2021 (Actual)
Primary Completion Date
August 17, 2026 (Anticipated)
Study Completion Date
August 17, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A study to evaluate the safety, pharmacokinetics and anti-tumor activity of RO7300490 as a single agent or in combination with atezolizumab. The study will consist of 3 parts: [Part 1] Dose-Escalation of RO7300490 as a single agent; [Part 2] Dose-Escalation of RO7300490 in combination with atezolizumab and [Part 3] Dose-Expansion of RO7300490 in combination with atezolizumab in selected cancer types.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
280 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1: Dose Escalation (RO7300490 Monotherapy)
Arm Type
Experimental
Arm Description
Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
Arm Title
Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)
Arm Type
Experimental
Arm Description
Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
Arm Title
Part 3: Dose Expansion (Disease-specific Expansion(s))
Arm Type
Experimental
Arm Description
Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
Intervention Type
Drug
Intervention Name(s)
RO7300490
Intervention Description
Participants will receive RO7300490, as described in the Arm Descriptions.
Intervention Type
Drug
Intervention Name(s)
Atezolizumab
Intervention Description
Participants will receive Atezolizumab, as described in the Arm Descriptions.
Primary Outcome Measure Information:
Title
Percentage of Participants with Adverse Events (AEs) (Parts 1 and 2)
Time Frame
Up to 36 months
Title
Percentage of Participants with Dose-Limiting Toxicities (DLTs) (Parts 1 and 2)
Time Frame
Up to 36 months
Title
Objective Response Rate (ORR) (Part 3)
Time Frame
Up to 48 months
Secondary Outcome Measure Information:
Title
Area Under The Curve (AUC) of RO7300490 (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Minimum Concentration (Cmin) of RO7300490 (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Maximum Concentration (Cmax) of RO7300490 (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Clearance (CL) of RO7300490 (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Volume of Distribution at Steady State (Vss) of RO7300490 (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Percentage of Participants with Anti-RO7300490 Antibodies (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Objective Response Rate (ORR) (Parts 1 and 2)
Time Frame
Up to 48 months
Title
Disease Control Rate (DCR) (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Duration of Response (DOR) (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Progression-Free Survival (PFS) On-Treatment (Parts 1, 2 and 3)
Time Frame
Up to 48 months
Title
Percentage of Participants With Adverse Events (AEs) (Part 3)
Time Frame
Up to 48 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Life expectancy of >= 12 weeks. Histologically confirmed diagnosis of locally advanced and/or metastatic solid tumors that are not amenable to standard therapy. Radiologically measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Agreement to provide protocol-specific biopsy material. Adverse Events (AEs) from prior anti-cancer therapy resolved to Grade =<1. Adequate performance status and cardiovascular, hematological, liver, renal and coagulation function. For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating eggs. For male participants: agreement to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating sperm. Exclusion Criteria: Known central nervous system (CNS) primary tumors or metastases, including leptomeningeal metastases, unless protocol-specific conditions are met. Active second invasive malignancy within two years prior to screening. Significant cardiovascular/cerebrovascular disease within 6 months prior to study treatment start. Any other diseases, metabolic dysfunction, physical examination finding or clinical laboratory finding that gives reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug. Prior allogeneic bone marrow transplantation or prior solid organ transplantation. Active or history of autoimmune disease. Known hypersensitivity to any of the components of RO7300490 formulation or to components of atezolizumab formulation. Pregnancy, lactation or breastfeeding. Dementia or altered mental status that would prohibit informed consent. Major surgery or significant traumatic injury within 28 days prior to the first study drug administration (excluding biopsies) or anticipation of the need for major surgery during study treatment. Treatment with radiotherapy, chemotherapy, hormonal therapy, targeted therapy, immunotherapy or investigational drug concurrent or within 28 days or 5 half-lives of the drug (whichever is shorter) before the first study drug administration.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reference Study ID Number: WP42627 https://forpatients.roche.com/
Phone
888-662-6728 (U.S. and Canada)
Email
global-roche-genentech-trials@gene.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
Rigshospitalet; Fase 1 Enhed - Onkologi
City
København Ø
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Gustave Roussy
City
Villejuif
ZIP/Postal Code
94805
Country
France
Individual Site Status
Completed
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Clinica Universitaria de Navarra; Servicio de Oncologia
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain
Individual Site Status
Recruiting
Facility Name
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Clinica Universidad de Navarra Madrid; Servicio de Oncología
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Western General Hospital; Edinburgh Cancer Center
City
Edinburgh
ZIP/Postal Code
EH4 2XU
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Guys and St Thomas Hospital; OHCT Clinical Trials
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Christie Hospital NHS Trust; Experimental Cancer Medicine Team
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

We'll reach out to this number within 24 hrs